Lupin receives USFDA's approval for generic version of Bayer's Beyaz Tablets

14 Jun 2018 Evaluate

Lupin has received final approval for its Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Bayer HealthCare Pharmaceutical Inc.'s (Bayer) Beyaz Tablets.

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of around $82.2 million in the US (IQVIA MAT April 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2144.40 -21.70 (-1.00%)
21-Jan-2026 15:04 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1614.90
Dr. Reddys Lab 1157.95
Cipla 1371.45
Zydus Lifesciences 875.90
Lupin 2144.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×